Comparing the current results to its competitors, Elutia Inc reported Revenue decrease in the 2 quarter 2026 year on year by -59.94 %, faster than the overall decrease of Elutia Inc 's competitors by -0.11 %, recorded in the same quarter.
Elutia Inc 's Comment on Competition and Industry Peers
The company operates in highly competitive markets characterized by rapid technological change. Its products primarily compete with other cardiovascular repair and human-derived acellular dermis products. Competitors in bovine pericardium and synthetic patch materials include Gore's Gore-Tex and Terumo's Vascutek. The company's SimpliDerm product competes with human-derived acellular dermis matrix meshes such as AbbVie's AlloDerm, MTF's FlexHD, Stryker's DermACELL, and Evergen's Cortiva. SimpliDerm also competes against animal-derived biological mesh products like AbbVie's Strattice and Integra's SurgiMend, as well as various synthetic mesh products. Additionally, the company faces competition in recruiting and retaining qualified personnel and in acquiring complementary technologies and licenses. Competitors identified in filings include AbbVie, Evergen, Gore, Integra, MTF, Stryker, and Terumo.
September 16, 2025
Elutia Inc. Sees Revenue Growth Amidst Industry Challenges, Highlighted by Positive Clinical Data for Biologic Envelopes In recent announcements, Elutia Inc. has showcased promising developments in both clinical data and financial performance, positioning the company favorably within a competitive landscape. The publication of new clinical data underscores the effectiveness of Elutia s antibiotic-eluting bioenvelopes in supporting stabilization of cardiac implantable electronic devices (CIED) and simplifying the reoperation process.The findings suggest that these biologic envelopes play a crucial role in managing CIED pockets, potentially transforming the current protocols for patients undergoing procedures ...
September 5, 2024
Elutia Inc. Begins a New Era in Cardiac and Neurostimulation Treatment with EluPro BioEnvelope By Elutia Inc. (Nasdaq: ELUT) has announced a significant milestone in the field of cardiac and neurostimulation therapy with the first successful patient implant of EluPro, the world’s first antibiotic-eluting biologic envelope, sanctioned by the U.S. Food and Drug Administration (FDA). The procedure was conducted by Dr. John Catanzaro at East Carolina University Health Medical Center, marking a pivotal advancement in medical device technology aimed at reducing infection rates associated with cardiac pacemakers and neurostimulators. Elutia Inc. is a leading company in the development of drug-eluting biomatrix ...
Adaptimmune Therapeutics Plc is a biopharmaceutical company that focuses on developing and commercializing innovative cancer immunotherapy products. Their business model revolves around leveraging their T-cell receptor platform to engineer and develop targeted immunotherapies for patients with various types of cancer.
Integra Lifesciences Holdings Corp's business model revolves around developing, manufacturing, and selling medical devices and instruments to healthcare providers.
Vir Biotechnology Inc is a clinical-stage immunology company that focuses on developing and commercializing innovative treatments for infectious diseases. Their business model revolves around the discovery and development of antibody therapies and other immunological approaches to combat a wide range of viral pathogens. They collaborate with leading research institutions and pharmaceutical companies to accelerate the development and commercialization of their products.
Valneva is a biotech company that specializes in the development and commercialization of vaccines. Their business model revolves around research, development, manufacturing, and distribution of vaccines for various infectious diseases. Valneva aims to partner with pharmaceutical companies, governments, and international organizations to bring safe and effective vaccines to the market, addressing global health challenges.
Sources:
Elutia Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Elutia Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
